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Background: Annexins are calcium dependent phospholipid binding proteins that are expressed in a wide variety
of tissues and implicated in various extra- and intracellular processes. In myocardial tissue, annexins A2, A5 and A6
are particularly abundant, of which the expression levels of annexin A6 has been found to be maximal. Conflicting
reports from transgenic mice overexpressing annexin A6 or null mice lacking annexin A6 showed imbalances in
intracellular calcium turnover and disturbed cardiac contractility. However, few studies have focussed on the
signalling module of annexin A6 in the heart either in normal or in pathological state.
Results: To identify the putative binding partners of annexin A6 in the heart, ventricular extracts were subjected to
glutathione S-transferase (GST)- annexin A6 pull down assay and the GST- annexin A6 bound proteins were
identified by mass spectrometry. The pull down fractions of ventricular extracts with GST-full length annexin A6 as
well as GST-C terminus deleted annexin A6 when immunoblotted with anti sarcomeric alpha (a)-actinin antibody
showed the presence of a-actinin in the immunoblot which was absent when GST-N terminus deleted annexin A6
was used for pull down. Overexpression of green fluorescent protein (GFP) tagged full length annexin A6 showed
z-line like appearance in cardiomyocytes whereas GFP-N termimus deleted annexin A6 was mostly localized to the
nucleus. Overexpression of GFP-C terminus deleted annexin A6 in cardiomyocytes showed aggregate like
appearance in the cytoplasm. Double immunofluorescent staining of cardiomyocytes with anti annexin A6 and anti
sarcomeric a-actinin antibodies showed perfect co-localization of these two proteins with annexin A6 appearing
like a component of sarcomere. Transient knockdown of annexin A6 in cardiomyocytes by shRNA significantly
enhances the contractile functions but does not affect the z-band architecture, as revealed by a-actinin
immunostaining in shRNA treated cells.
Conclusions: In overall, the present study demonstrated for the first time that annexin A6 physically interacts with
sarcomeric a-actinin and alters contractility of cardiomyocytes suggesting that it might play important role in
excitation and contraction process.
Background
T h ea n n e x i n sc o n s t i t u t eaf a m i l yo fh i g h l yc o n s e r v e d
proteins that are characterized by their Ca
2+-dependent
binding to phospholipids [1]. Annexins are expressed in
a wide variety of tissues and implicated in various extra-
and intracellular processes including mitogenic signal
transduction, differentiation and membrane trafficking
events [2]. However, the exact biological role of each
annexin remains unknown.
In myocardial tissue, annexins A2, A5 and A6 are par-
ticularly abundant [3-7]. AnxA6 is the most abundant
annexin in myocardium [8,9]. It is involved in exocyto-
sis, membrane trafficking and Ca
2+ signaling [10]. Con-
flicting reports demonstrated that it is increased at the
onset of heart failure in guinea pig [7] and slightly
increased or remain unchanged in failing human hearts
[11]. Transgenic mice overexpressing AnxA6 developed
dilated cardiomyopathy [12], impaired cardiac contracti-
lity and showed enhanced intracellular Ca
2+ turnover
[13]. In contrast, AnxA6 null mice displayed increased
rate of Ca
2+ removal in myocytes and enhanced contrac-
tility [14].
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of a unique N terminal domain and C terminal core
domain that varies in length and amino acid composi-
tion. The N terminal region is thought to confer func-
tional diversity to the annexin protein. The C terminal
domain is formed by either a four or eightfold (in case
of AnxA6) repeats of approximately 70 amino acid, each
repeat carrying a Ca
2+ binding site [15].
The mechanism by which AnxA6 alters contractile
functions at the cellular level is not clear. We hypothe-
sized that AnxA6 might physically interact with the sar-
comeric proteins in cardiomyocytes to alter the
contractile functions of heart. Therefore, to gain insight
i n t ot h ef u n c t i o n a lr o l eo fA n x A 6 ,w eh a v ea n a l y s e di t s
interacting partners by mass spectrometry and examined
the functional significance of AnxA6 knockdown in
cardiomyocytes.
Results
Binding partners of AnxA6 in heart
To identify the potential interacting proteins of AnxA6
in heart, in vitro binding of whole heart homogenate
(WHH) proteins with GST-AnxA6 fusion protein was
conducted (Figure 1). The solubilised WHH was
applied to GST-AnxA6 bound glutathione-sepharose
4B beads. The proteins not retained by GST-AnxA6
were mostly removed during washing and those bound
to GST-AnxA6 were eluted (Figure 1A, lane 2) and
subjected to mass spectrometric analysis. The mass
spectrometry analysis showed that a-actinin was one
of the major proteins bound to GST-AnxA6 (Addi-
tional file 1). Therefore, it is apparent that a-actinin
might be a potential interacting partner of AnxA6 in
the heart. However, the other proteins obtained by
mass spectrometry were also likely to interact with
AnxA6 since those too were retained by GST-AnxA6
(Additional file 1).
To validate the interaction of AnxA6 with a-actinin in
cardiomyocytes, immunoblotting analysis of GST-
AnxA6 pull-down fraction with anti sarcomeric a-
actinin antibody was conducted. As shown in Figure 1
(B), the GST-AnxA6 pull-down fraction of the WHH
showed the presence of a-actinin. Since AnxA6 is a
phospholipid binding protein and a-actinin is known to
bind with phosphatidylinositol bisphosphate (PIP2)
[1,16], we examined whether binding of AnxA6 with a-
actinin in heart homogenate depends on PIP2. In vitro
binding assay clearly demonstrates that delipidation of
heart homogenate does not influence interaction of
AnxA6 with a-actinin (Figure 1C).
To further validate the interaction of AnxA6 with
a-actinin, WHH was directly subjected to immunopre-
cipitation with anti sarcomeric a-actinin antibody fol-
lowed by western blotting with AnxA6 antibody. As
shown in Figure 1(D), AnxA6 was present in the
immunoprecipitate indicating that these two proteins
interact in vivo. To search for the domains of AnxA6
that could serve for the interaction with a-actinin, in
vitro binding assay was conducted using various dele-
tion mutants of GST-AnxA6 fusion proteins (Figure
2B). As shown in Figure 2B, SDS-PAGE analysis fol-
lowed by in vitro binding experiment with GST fused
proteins exhibited significant binding to a-actinin with
AnxA6 (lane 1) or mutants lacking domains C1-C3
(GST-AnxA6 ΔC1 - GST-AnxA6 ΔC3; lanes 8-10).
However, the interaction between AnxA6 and a-
actinin was completely abolished in the AnxA6
mutants lacking domains N1-N3 (GST-AnxA6 ΔN1-
GST-AnxA6 ΔN3; lanes 3-5, Figure 2B).
Localization of GFP-AnxA6 and its deletion mutants in
cardiomyocytes
To examine the subcellular localization of AnxA6 in
cardiomyocytes, GFP-AnxA6 was introduced into neo-
natal rat ventricular myocytes (NRVM) and visualized
under fluorescence microscope after 48 hrs. As shown
in Figure 3A, GFP-AnxA6 was localized to the cytoske-
letal structure, which closely resembles the Z discs typi-
cally seen in cardiomyocytes. However, GFP-AnxA6
ΔN1 was mostly localized to the nucleus whereas GFP-
AnxA6 ΔC1 was localized to the cytosol and appeared
to be large aggregates or vesicles.
To examine whether knock down of AnxA6 expres-
sion alters z-band organization, NRVM were transfected
with AnxA6 shRNA (KD) or scrambled sequence
(CON) and after 72 h subjected to immunofluorescence
with anti-sarcomeric a-actinin antibody. As shown in
Figure 3B, the striated pattern in cardiomyocytes
remained unaffected when AnxA6 was knocked down.
Co-localization of AnxA6 with a-actinin in cardiomyocytes
The interaction of AnxA6 with a-actinin in situ was
examined in NRVM by immunofluorescence micro-
scopy. The pattern of AnxA6 localization in cardiomyo-
cytes was similar to a-actinin and both displayed
striated distribution similar to z-discs of sarcomere
(Figure 4). The extent of co-localization was enumerated
by generating the line profiles of fluorescence intensities
of tetramethylrhodamine isothiocyanate (TRITC) for
a-actinin and fluorescein isothiocyanate (FITC) for
AnxA6 (Figure 4 lower panel). These fluorescence pro-
files demonstrates (through randomly chosen line over
the merged images) the parallel pattern of spatial distri-
bution of AnxA6 and a-actinin signals, indicating a high
degree of co-localization of these two proteins, which
was further strengthened by Pearson’s correlation coeffi-
cient as high as 0.898 ± 0.014, obtained from co-
localization analysis.
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To consider the mechanistic effect of AnxA6 in cardio-
myocytes, adult rat ventricular myocytes were (ARVM)
transfected with AnxA6 shRNA (KD) or scrambled
sequence (CON). Mechanical properties were studied in
GFP-positive cardiomyocytes using video-based edge
detection system (IonOptix) as described in the “Methods”
section. AnxA6 shRNA transfected cells exhibited a signif-
icant increase in percent shortening (Figure 5C), rate of
contraction (+ dL/dt) (Figure 5A) and rate of relaxation
(-dL/dt) (Figure 5B) as compared to control cells.
Discussion
The present study demonstrates AnxA6 to be a member
of the z-disc and its involvement in cardiomyocyte con-
tractility. Therefore, altered level of AnxA6 might impair
cardiac excitation and contraction cycles, which could
explain the contractile abnormality in AnxA6 transgenic
as well as knockout mice [12,14]. Though the histo-
chemical localization of Anx6 has been reported in gui-
nea pig heart [7], the present study clearly demonstrates
that AnxA6 physically interacts with a-actinin. It is
known that a-actinin helps in crosslinking of actin in
cardiomyocytes and is an important component of the
contractile unit i.e. sarcomere [17].
Since AnxA6 mutant lacking residues 1-250 amino acids
(aa) (N3) fails to bind with a-actinin in WHH, it is likely
that this region of AnxA6 plays a critical role in mediating
binding with a-actinin. On the other hand, residues
435-673 aa, which include domains C1-C3 and C terminal
tail, are not involved in this interaction; since the deletion
of these residues does not have any effect on in vitro bind-
ing. It has been demonstrated earlier that AnxA6 acts as
the binding partner of calspectin and regulates bundling of
F-actin in vitro [18]. Recently, it has also been shown that
AnxA6 interacts with actin exclusively through its N term-
inal domain in cardiomyocytes [19]. It has been demon-
strated earlier that AnxA6 is predominantly located at the
sarcolemma and intercalated discs as revealed by the trans-
verse sections of the left ventricle [9,11]. However, the
exact subcellular localization of AnxA6 in isolated myo-
cytes was not known. The present study clearly demon-
strates the localization of AnxA6 in the z-disc of
cardiomyocytes. Furthermore, we specifically show that
Figure 1 Identification of putative AnxA6 binding partner(s) in rat heart. A. Purified GST-AnxA6 (A6) affinity beads or GST affinity beads (V)
were incubated with NP-40 solubilised WHH (1.5 mg) and the bound proteins (interactome) were separated in 12% SDS-PAGE, stained with
Coomassie (lane 2) and analysed via LC MS/MS. B. In vitro binding assay: Solubilised whole heart homogenates (WHH) were incubated with GST
affinity beads (vector) or AnxA6-GST affinity beads and the bound proteins collected in elute were separated by 10% SDS-PAGE followed by
immunoblotting analysis with anti sarcomeric a-actinin antibody. C. In vitro binding assay with lipid depleted WHH: Solubilised WHH or
delipidated WHH incubated either with GST-AnxA6 affinity beads or GST (vector) affinity beads and the bound proteins in elute were separated
by 10% SDS-PAGE followed by immunoblotting analysis with anti sarcomeric a-actinin antibody. D. Immunoprecipitation: The whole heart
homogenate (300 μg) was subjected to immunoprecipitation with anti sarcomeric a-actinin antibody followed by western blotting with anti-
AnxA6 antibody.
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through its N terminus. Therefore, it is likely that binding
of AnxA6 to cardiac sarcomere is mediated via its N term-
inal domains through a-actinin. Interestingly, z-band orga-
nization in cardiomyocytes is not altered when AnxA6 is
knocked down. Therefore, absence of AnxA6 does not
alter the structural organization of the sarcomeric z-lines.
Interaction of AnxA6 ΔC1 with a-actinin shown by in
vitro binding experiment indicates that residues required
for binding with a-actinin is retained in the purified
mutant. Though, in vitro binding experiment shows
interaction of GST-AnxA6 ΔC1 with a-actinin, it is not
clear why the mutant fails to localize to z-discs in situ.
Such discrepancy appears to be restricted to in vitro/in
vivo situations solely. Yet, it is plausible that deletion of
C terminal sequences affects translocation process
of AnxA6 into the z-disc. Moreover, in situ over-
expression of this mutant most likely induces irregular
accumulation of juxtanuclear vesicles of the mutant protein.
It is evident that interaction of AnxA6 with a-actinin
occurs via N terminal domain and hence GFP-AnxA6
ΔN1 fails to localize to z-disc when overexpressed in car-
diomyocytes. However, it is not clear why this mutant is
localized to nucleus. Nuclear localization of AnxA6 in
the endothelial and smooth muscle cells of cardiac origin
has been reported earlier [8]. In the present study locali-
zation of GFP-AnxA6 ΔN1 to the nucleus may be due to
the structural transition in the mutant protein regulating
its transport and import into the nucleus.
The cytoskeleton of the heart muscle cell is crucially
important for the contractile function of the heart. The
basic contractile unit of cardiomyocyte is the sarcomere.
Actin filaments are directly connected to the z-disc of
the sarcomere. a-Actinin is an important actin cross-
linking molecule, which exists as an anti-parallel homo-
dimer and orients the actin-binding domains at opposite
ends, allowing each dimer to bind two actin filaments,
leading to the formation of bundles [17]. The
Figure 2 N-terminus of AnxA6 mediates binding with a-actinin. A. Scheme representing AnxA6 deletion mutants. The full length AnxA6
contains eight repeat domains and associated linker residues (residues 1-673). Deletion mutants GST-AnxA6 ΔN1 lacks N terminal tail and repeat
domain 1 (residues 1-89); GST-AnxA6 ΔN2 lacks N terminal tail, repeat domains N1 and N2 (residues 1-163); GST-AnxA6 ΔN3 lacks N terminal tail,
repeat domains N1, N2 and N3 (residues 1-250); GST-AnxA6 ΔC1 lacks C terminal tail and repeat domain C1 (residues 600-673); GST-AnxA6 ΔC3
lacks C terminal tail and repeat domains C1, C2 and C3 (residues 435-673). GFP-AnxA6 D N1 lacks N terminal tail and repeat domain 1 (residues
1-89) and GFP-AnxA6 D C1 lacks C terminal tail and repeat domain C1 (residues 600-673). B. Solubilised WHH was incubated with GST affinity
beads (vector) or various mutants of AnxA6 lacking domains N1-N3 (GST-AnxA6 ΔN1- GST-AnxA6 ΔN3) or mutants lacking domains C1-C3 (GST-
AnxA6 ΔC1 and GST-AnxA6 ΔC3). The presence of a-actinin in the bound fractions was detected by immunoblotting analysis with anti
sarcomeric a-actinin antibody (arrow head).
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2+ binds to troponin C, moving the tro-
pomyosin complex off the actin-binding site allowing
the myosin head to bind to the actin filament during
cardiac excitation and contraction. The intracellular
connections between the z-disc of the sarcomere and
the sacolemma allow transmission of force developed by
the myofilaments [17]. Here we clearly demonstrate the
localization of AnxA6 in the z-disc of sarcomere in car-
diomyocytes via the mediation of a-actinin.
In vivo experiments reported impaired cardiac con-
tractility in AnxA6 transgenic mice whereas enhanced
contractility was observed in cardiomyocytes isolated
from AnxA6 knock out mice (13, 14). Consistent with
these in vivo observations here we show that transient
knock down of AnxA6 significantly (P < 0.05) aug-
ments percent shortening, rate of shortening (+dL/dT)
and rate of relengthening (-dL/dT) as compared to
control cardiomyocytes indicating that contractility of
cardiomyocytes is enhanced. Hence, AnxA6 likely
serves as a regulator of cardiac contractility by its asso-
ciation with the contractile proteins in cardiomyocyte.
Therefore, interaction of AnxA6 with a-actinin
signifies its potential role in cardiac mechano-
transduction.
Conclusions
This study is a maiden report showing the spatial co-
localization and physical interactions of AnxA6 with sar-
comeric a-actinin. The functional significance of such
interaction might be important for regulating contractile
properties of cardiomyocytes. Thus, AnxA6 may have a
significant role in cardiac pathophysiology.
Methods
Material
Collagenase type 2, anti sarcomeric a-actinin primary
antibody, Protein A agarose were purchased from Sigma
Chemical Co (St. Louis, MO, USA). All other primary
and secondary antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, USA).
Animal
Sprague-Dawley male rats for the present study were
available from Institute’s animal facility. The animals
were handled as per the guidelines of the animal ethics
committee of this institute and the Committee for the
Purpose of Control and Supervision of Experiments on
Animals, Ministry of Social Justice and Empowerment,
Government of India.
Figure 3 Subcellular localization of GFP-AnxA6 fusion protein in cardiomyocytes. A. Representative images showing expressions of AnxA6
and its mutants in NRVM. The GFP expression was examined under Olympus (IX71) microscope after 96 hrs of transfection. The GFP-AnxA6
appears to be localized to sarcomeric z-lines (arrow), GFP-AnxA6 ΔN1 is localized to the nucleus (arrow) and GFP-AnxA6 ΔC1 is expressed as
aggregate like structures in cytoplasm (arrow), The experiment was repeated with three different batches of myocytes preparation (n = 3). Scale
bar represents 10 μm (63×). B. Sarcomeric z-line organization showing striations in AnxA6 knocked down cardiomyocytes. NRVM were
transfected with AnxA6 shRNA or scrambled constructs and z-lines were visualized by immunofluorescence with a- actinin antibody after 72 h.
Transfected cardiomyocytes were selected based on the GFP expression. Representative images were randomly chosen from a pool of cells
drawn from 3 independent experiments. Scale bar represents 15 μm (40×).
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assay
Cardiac tissue from wild type SD rat was homogenized in
an extraction buffer containing 10 mM Tris, pH 8.5,
0.01% (v/v) SDS, 20 mM NaCl, 0.01% (v/v) Nonidet P-40,
5m ME D T A ,2m MD T T ,a n dp r o t e a s ei n h i b i t o r s .T h e
homogenate was centrifuged for 10 min 3000 × g at 4°C,
and the supernatant was used for GST pull down assay.
Generation of GST fusion proteins of AnxA6 and its
mutants for in vitro binding assay
cDNA encoding the full-length AnxA6 and its mutants
lacking various domains in the amino-terminal and car-
boxyl terminal regions were cloned into GST fusion vec-
tor pGEX-4T-1 (GE-Amersham). Standard molecular
cloning techniques were used to manipulate DNA. The
primers are listed in additional file 2. The scheme of con-
structs is summarized in Figure 2A. Expression and puri-
fication of the fusion proteins were performed according
to the protocol of the manufacturer (GE-Amersham).
In vitro binding assay
In vitro binding experiment was performed as described
earlier [20]. Equal amounts of recombinant GST and
GST-AnxA6 were bound to glutathione-sepharose and
mixed with 1.5 mg of whole heart homogenates at 4°C
for 5 hours. Nonspecific binding was determined by car-
rying out the binding with GST, instead of GST-AnxA6.
The Co-complexed proteins after washing in the cold
washing buffer (10 mM Tris, pH 8.5, 0.01% (v/v) Noni-
det P-40, 5 mM EDTA, 2 mM DTT, 0.05% (v/v) SDS)
were eluted with 1 volume of 20 mM glutathione and
150 mM NaCl in 50 mM Tris/HCl, pH 8. After washing
the proteins were separated by heating for 5 mins at
90°C in the SDS-PAGE sample buffer (50 mM Tris, pH
Figure 4 Colocalization of AnxA6 with a-actinin in
cardiomyocytes. The representative images shown are
endogenous expression of AnxA6 (a) and a-actinin (b) in the same
cell and their colocalization pattern (c). The line profile for
quantification of colocalization (d) was done using the merged
image (inset) of AnxA6 and sarcomeric a-actinin. The images
represent results of three different experiments with separate
batches of myocyte preparation. Scale bar represents 10 μm (100×).
Figure 5 Contractility in AnxA6 knocked down cardiomyocytes. ARVM were transfected with AnxA6 shRNA (KD) or scrambled shRNA (CON)
constructs and their contractile parameters were determined in GFP-positive cardiomyocytes. Peak cell shortening, percentage of shortened cell
length (A); -dL/dt, maximal velocities of cell shortening (B); +dL/dt, maximal velocities of cell relengthening (C) were the contractile parameters.
Bars represent the mean ± SEM [n = 6], p < 0.05.
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blue, 10% (v/v) glycerol) and were then detected by the
Coomassie blue staining. Interacting proteins were ana-
lysed using the LC MS or subjected to immunoblotting
analysis for validation.
Mass spectrometric analysis to search for the interacting
partners
Interacting proteome were analysed using LC MS/MS as
described elsewhere [21]. Raw files were searched for
fully tryptic peptides against the IPI Rat database using
Sequest software.
Western blot analysis
Equal amounts of GST or GST-AnxA6 pull down frac-
tions were resolved onto 10% SDS polyacrylamide gels
and subjected to immunoblotting analysis with a-actinin
antibody following previously described method [22].
Delipidation of WHH
Delipidation of WHH was done with little modification
of previously described method. [23,16].
Immunoprecipitation
For immunoprecipitation (IP) experiment, a-actinin anti-
body was pre-incubated with Protein A agarose for
4 hours at 4°C. After the protein A agarose got saturated
with the antibody, it was added to 1 mg of WHH and
was incubated overnight at 4°C. The IP pellets thus
obtained were washed twice for 15 minutes each using
cold wash buffer and one wash using PBS-T at 4°C. Iden-
tification of AnxA6 in immunoprecipitate was performed
by western blot analysis with anti-AnxA6 antibody.
Isolation rat ventricular cardiomyocytes
Neonatal rat ventricular cardiomyocytes (NRVM) were
prepared by previously described method [24]. Adult
rat ventricular cardiomyocytes (ARVM) from Sprague-
Dawley rats were isolated as reported earlier with
some minor modifications [25]. The pellets contained
90-97% rod shaped viable ventricular myocytes, were
resuspended in glucose-free KH buffer. Approximately
5.0 × 10
4 rod-shaped cells were plated on 18-mm lami-
nin-coated coverslips and maintained in a 5% CO2
incubator.
Cloning for over-expression of AnxA6 into
cardiomyocytes
cDNAs encoding full length AnxA6 or AnxA6 lacking
residues 1-89 aa (GFP-AnxA6 ΔN1) or AnxA6 lacking
residues 600-673 aa (GFP-AnxA6 ΔC1) were amplified
using gene specific primers and cloned into HindIII/PstI
sites of pEGFP-N1 vector (BD Biosciences Clontech).
About 2.8 μg of DNA was used to transfect freshly
isolated NRVM (8 × 10
5 cells) through electroporation
using ‘Rat Cardiomyocyte-Neonatal Nucleofector TM
Kit (amaxa GmbH)’, following manufacturer’sp r o t o c o l
[26]. Expression of EGFP-AnxA6 and its mutants were
monitored at 488 nm. The empty vector was also trans-
fected as control.
Annexin A6 knock down
To transiently knock down AnxA6 expression in cardio-
myocytes, 29 mer shRNA construct against rat AnxA6
in pGFP-V-RS vector was obtained (OriGene Technolo-
gies Inc, Rockville, MD, USA). Scrambled shRNA was
employed as control. Transfection was performed using
Lipofectamine™ LTX reagent (Invitrogen, Carlsbad,
USA). About 30% ARVM were found to be transfected
with shRNA constructs based on GFP signals. Due to
the limitation of transfection efficiency in ARVM, knock
down efficiency was quantified in human embryonic
kidney (HEK) cells where nearly 100% cells were GFP
positive [Additional file 3A]. Cell extracts were prepared
72 h after transfection with shRNA and immunoblotting
with anti-AnxA6 antibody was conducted. As shown in
additional file 3B and 3C, 60% knock down of Anx A6
was achieved with AnxA6 shRNA sequence in compari-
son to the scrambled shRNA sequence in the trans-
fected cells.
Cell contractility measurement
The mechanical properties of ARVM were assessed
using a video-based edge detection system (IonOptix) as
previously described [26]. In brief, laminin-coated cover-
slips with cells attached were placed in a chamber
mounted on the stage of an inverted microscope (Nikon
Eclipse TE-100F) and superfused (about 1 ml/min at
25°C) with Tyrode buffer (137 mM NaCl, 5.4 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and 10
mM HEPES (pH 7.4)). The cells were field stimulated at
a frequency of 1 Hz (30 V) using a STIM-AT stimula-
tor/thermostat placed on HLD-CS culture chamber/stim
holder (Cell Micro Controls). Changes in cell length
during shortening and relengthening were captured in
GFP-positive cardiomyocytes and analyzed using soft
edge software (IonOptix).
Immunofluorescence
The localization of AnxA6 and a-actinin were examined
by immunofluorescence using specific antibodies against
each protein as described earlier [24].
Statistical analysis
T h er e s u l t sa r ep r e s e n t e da st h em e a n±S . E . M .E a c h
experiment was conducted independently at least three
times. A level of p < 0.05 was considered the threshold
for statistical significance.
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Additional file 1: List of the possible interacting partners of AnxA6.
Additional file 2: List of primers.
Additional file 3: A. Expression of pGFP-V-RS/AnxA6 shRNA
construct in HEK cells. Transfected cells were analyzed after 72 hours
for GFP expression and approx.100% cells were found to be GFP-positive.
Scrambled showed similar results. Scale bar represents 100 μm (10×). B.
Immunoblot analysis were performed in AnxA6 shRNA or scrambled
transfected HEK cells at 72 hours post transfection with anti AnxA6
antibody or anti actin antibody (Loading control). C. Quantification of
AnxA6 knockdown in HEK cells. Densitometry analysis (NIH ImageJ)
shows approx. 60% knockdown of AnxA6 as compared to scrambled.
Data were normalized to the values of loading control and plotted as
mean ± S.E.M. p < 0.05.
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